A Phase 4 interventional study of SGLT2 inhibitor (Dapagliflozin 10mg) in Congenital Heart Disease, Repaired Tetralogy of Fallot (rTOF) and Pulmonary Regurgitation, sponsored by The University of Hong Kong. Recruiting at 1 site in Hong Kong. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by The University of Hong Kong · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Repaired Tetralogy of Fallot (rTOF) is the leading cause of congenital cyanotic heart disease worldwide, involving up to 7-10% of congenital heart disease. With advances in open-heart surgical repair techniques and medical therapies, there is a significant increase in patients with rTOF surviving till late adulthood. One sequalae that nearly all rTOF patients develop during their lifetime is significant pulmonary regurgitation. Pulmonary regurgitation causes progressive right ventricular dilatation and systolic dysfunction, which in turn impairs cardio-pulmonary function and overall survival.
There is currently no pharmacological therapy proven to improve cardio-pulmonary function in rTOF patients. In a double-blind, placebo controlled, randomized controlled trial involving 33 rTOF patients, the use of beta-adrenergic receptor blocker Bisoprolol failed to improve maximal oxygen uptake (VO2 max) in the treatment group. Furthermore, there was no significant change in dimension of right ventricle on cardiac imaging, or heart failure biomarkers including brain natriuretic peptide (BNP) and atrial natriuretic peptide (ANP). In the APPROPRIATE trial involving 64 patients, angiotensin-converting-enzyme inhibitor (ACEI) Ramipril similarly failed to improve VO2 max despite an improved right ventricular long-axis shortening. In REDEFINE trial, 95 rTOF patients were randomized in to receive angiotensin receptor blocker (ARB) Losartan and control. At the end of study, there was no significant difference between the two groups in VO2 max, right ventricular ejection fraction, and other key outcomes.
Sodium-glucose cotransporter 2 (SGLT2) inhibitor is a promising therapy for rTOF patients. Clinical trials consistently demonstrated that SGLT2 inhibitors reduce heart failure hospitalization and mortality among patients with heart failure with or without diabetes mellitus. There have been growing body of evidence that demonstrate that SGLT2 inhibitors improve right ventricular function. In a preclinical study of rat with pulmonary hypertension induced right ventricular failure, empagliflozin was found to reduce pulmonary pressure, alleviate right ventricular hypertrophy and reduce myocardial fibrosis. In a pilot study involving 10 patients with adult congenital heart disease and systemic right ventricular failure, SGLT2 inhibitors improved cardio-pulmonary function as reflected by 6-minute walk test performance and New York Heart Association functional status. Most recently, investigators from DAPA-SERVE randomized controlled trial reported that among 92 patients with systemic right ventricular failure, those randomized to receive SGLT2 inhibitors had superior systemic right ventricular function with larger fractional area change (FAC) and more negative free-wall global longitudinal strain. Nevertheless, as these trials involve patients with right ventricular connections to the systemic circulation rather than pulmonary circulation in rTOF, it is uncertain whether the trial results can be extrapolated to the rTOF population. The critical knowledge gap our proposed randomized controlled trial seeks to address is whether SGLT2 inhibitors improve cardio-pulmonary function in rTOF patients.
Patients with repaired TOF fulfilling inclusion and exclusion criteria will be recruited from Queen Mary Hospital, Hong Kong.
Patients who fulfill the inclusion and exclusion criteria will be interviewed by research staff and given a detailed explanation of the clinical trial. Written informed consent will be obtained if the patient agrees to enroll in the trial.
Assessments will be performed at Visit 1 (week 1): Review of medical history and history taking, Physical examination of vital signs (including blood pressure, pulse rate, and oxygen saturation by pulse oximetry), and cardiovascular system (12-lead electrocardiography (ECG), Blood tests (if not already done within 3 months): Complete blood count, Renal function test, Liver function test, Calcium and phosphate levels, N-terminal pro b-type natriuretic peptide (Nt-pro-BNP), High sensitive troponin T, Creatinine kinase, Hemoglobin A1c (HbA1c), Fasting glucose, Lipid profile , Erythropoietin, Multi-omic studies including proteomics, metabolomics, and lipidomics, Genetic test and geneticist consultation, Echocardiography (if not already done within 3 years), Cardiopulmonary test (CPX), Urine pregnancy test in women of childbearing age.
Randomization will be performed on the day of recruitment. An allocation sequence will be generated prior to initiation of the clinical trial using random numbers generated by computer. After entering a subject's information on the clinical trial system, the allocated group for the subject will be revealed. If a subject found to be ineligible for the clinical trial after randomization, the original assignment will be allocated to the next eligible subject. Subjects will be randomized in a 1:1 ratio to 1 of the 2 treatment arms:
CPX will be performed on Visit 1 (week 4 ± 1) and Visit 3 (week 12 ± 1) under supervision of cardiologist blinded to randomization results. VO2 max, which represent the maximal amount of oxygen consumed during peak exercise, will be measured. In addition, other parameters including metabolic equivalents (METs) achieved, oxygen pulse, anaerobic threshold (VO2 AT), ventilatory equivalent for oxygen (VE/VO2) will be evaluated. Participant will concurrently be Apple Watch Series 9 (Apple, USA) smartwatch for pre- and post-SaO2 and VO2max assessment.
Echocardiography will be performed on Visit 1 and Visit 3 by independent echocardiographer blinded to randomization result. Right ventricular function will be assessed by measuring fractional area change (FAC), tricuspid annular plane systolic excursion (TAPSE), lateral tricuspid annulus peak systolic velocity (RVS'). Right ventricular diastolic diameter including basal (RVD1), mid ventricle (RVD2) and longitudinal (RVD3) will be measured. Tricuspid regurgitation severity will be graded using vena contracta with \<0.2 cm as mild, 0.2-0.6 cm as moderate, and ≥0.7 cm as severe. Pulmonary regurgitation severity will be graded using semi-quantitative approach using right ventricular outflow view and parasternal short axis view with pressure half time \<100 ms to be graded as severe.
992 studies on the registry are indexed under Heart Defects, Congenital; 252 are open to participants now.
This study's planned enrollment of 106 is above the median of 60 across 508 interventional studies indexed under Heart Defects, Congenital.
Browse Heart Defects, Congenital studies →The University of Hong Kong is the lead sponsor of 1,295 studies on the registry; 351 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dapagliflozin 10mg once daily orally from Visit 1 (Week 1) to Visit 3 (Week 12 ± 1)
Drug: SGLT2 inhibitor (Dapagliflozin 10mg)
Routine care
Subjects in SGLT2 inhibitor Group will take dapagliflozin 10mg once daily orally from Visit 1 (Week 1) to Visit 3 (Week 12 ± 1)
Maximal oxygen uptake (VO2 max) on cardiopulmonary exercise (CPX) at 3 months
Efficacy of SGLT2 inhibitors for improving cardiopulmonary function as assessed the maximal oxygen uptake (VO2 max) on cardiopulmonary exercise testing in rTOF patients at 3 months
Time frame: At Visit 3 (3 months)
Right ventricular systolic function and dimension
Effect of SGLT2 inhibitors on right ventricular dimension and function in rTOF patients as assessed by performing echocardiography at 3 months
Time frame: At Visit 3 (3 months)
Pulmonary and tricuspid regurgitation severity
Effect of SGLT2 inhibitors on as pulmonary and tricuspid regurgitation severity as assessed by echocardiography at 3 months
Time frame: At Visit 3 (3 months)
Other cardiopulmonary test (CPX) parameters
Metabolic equivalents (METs) achieved, oxygen pulse, anaerobic threshold (VO2 AT), and ventilatory equivalent for oxygen (VE/VO2) are assessed during CPX for effect of of SGLT2 inhibitors in rTOF patients
Time frame: At Visit 3 (3 months)
Cardiac biomarkers level
Cardiac biomarkers level, including NT-proBNP and high sensitive troponin T in rTOF patients at 3 months as assessed via blood tests for effect of SGLT2 inhibitors
Time frame: At Visit 3 (3 months)
Minnesota Living with Heart Failure Questionnaire/ Kansa City Cardiomyopathy Questionnaire (KCCQ) score
Minnesota Living with Heart Failure Questionnaire/ Kansa City Cardiomyopathy Questionnaire (KCCQ) score as completed with rTOF patients for effect of SGLT2 inhibitors
Time frame: At Visit 3 (3 months)
Time to first occurrence of clinical events
Time to first occurrence of clinical events, including heart failure hospitalization, incident arrhythmia, and cardiovascular mortality in 3 months safety as assessed for tolerability of SGLT2 inhibitors in rTOF patients
Time frame: At Visit 3 (3 months)
Occurrence of adverse events
Occurrence of adverse events in 3 months as assessed for safety and tolerability SGLT2 inhibitors in rTOF patients
Time frame: At Visit 3 (3 months)
Plan to share: Undecided
Started May 2025 (actual). Primary completion is estimated for Dec 2026, 19 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dapagliflozin